May 12, 2020 / 7:18 AM / in 15 days

BRIEF-Lundbeck expects impact on sales in Q2, Q3 from diminishing stockpiles - CFO

May 12 (Reuters) - Lundbeck:

* CFO SAYS SALES WILL PROBABLY BE AFFECTED BY DIMINISHING DRUG STOCKS IN SECOND AND THIRD QUARTER

* CFO SAYS A LONG RANGE OF INFUSION CENTRES AND MIGRAINE EXPERTS HAVE ALREADY BOUGHT VYEPTI DRUG FOR TREATMENT OF PATIENTS

* CFO SAYS SO FAR LUNDBECK IS AT THE EXPECTED LEVEL REGARDING ACCESS TO DIFFERENT INSURANCE PLANS IN THE UNITED STATES FOR VYEPTI

* CFO SAYS HE EXPECTS CLINICAL TRIALS CURRENTLY ON HOLD DUE TO THE CORONAVIRUS PANDEMIC TO RESUME WITHIN ONE TO THREE MONTHS Source text for Eikon: Further company coverage: (Reporting by Nikolaj Skydsgaard)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below